

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Attorney Docket No. 056291-5215		Application No. 10/554,202		
				Applicants: Robert Hugh BRADBURY et al.				
				Filing Date: October 24, 2005		Group Art Unit: 1624		
U.S. PATENT DOCUMENTS								
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date	
	1.	US 2003/0186995	October 2, 2003	Kath et al.				
	2.	US 2004/0048880	March 11, 2004	Himmelsbach et al.				
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./								
FOREIGN PATENT DOCUMENTS								
		Document No.	Date	Country	Class	Sub-Class	Translation	
	3.	CA 2476008	October 9, 2003	Canada				
	4.	CA 2543649	May 12, 2005	Canada				
	5.	WO 01/21596	March 29, 2001	WIPO				
	6.	WO 2004/046101	June 3, 2004	WIPO				
	7.	WO 2005/041973	May 12, 2005	WIPO				
	8.	WO 2005/097134	October 20, 2005	WIPO				
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./								
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)								
	9.	Ballard et al. "Developing a small molecule erbB2 inhibitor: challenges with optimising DMPK properties" Poster - Presented at DMDG Cambridge (February 6, 2008) .						
	10.	Ballard et al. "Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorg Med Chem Lett. 17(22):6326-6329 (2007) .						
	11.	Barlaam et al. "A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorganic & Medicinal Chemistry Letters 18(2):674-678 (2008) .						
	12.	Barlaam et al. "Indazolylamino/Anilinoquinazolines Bearing a C-5 substitution as erbB2 kinase inhibitors: Structure-activity relationships and identification of a candidate drug" at AACR in 2007 .						
	13.	Barlaam et al. "Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorganic & Medicinal Chemistry Letters 18(6):1799-1803 (2008) .						
	14.	Barlaam et al. "Indazolylamino/Anilinoquinazolines Bearing a C-5 Substitution As erbB2 Kinase Inhibitors: Structure-Activity Relationships and Identification of a Candidate Drug" Poster number P044, presented at XXth International Symposium on Medicinal Chemistry (EFMC-ISMIC 2008), Vienna, Austria, August 31 - September 4, 2008 .						
	15.	Cockerill et al. "Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFR and c-erbB-2" Bioorganic & Medicinal Chemistry Letters 11(11):1401-1405 (2001) .						
	16.	Ducray et al. "Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors" Bioorganic & Medicinal Chemistry Letters 18(3):959-962 (2008) .						
	17.	Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13(4):637-640 (2003) .						
	18.	Harris et al. "Systematic variation of a key quinazoline core" Presented at the XXII European Colloquium on Heterocyclic Chemistry (XXII ECHC-2006) Bari, Italy, September 2-6, 2006 .						
	19.	Hennequin et al. "N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor" J Med Chem. 49(22):6465-6488 (2006) .						
	20.	Jani et al. "Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor" Cancer Research 67(20):9887-9893 (2007) .						
Examiner		/Tamthom Truong/			Date Considered			05/07/2009
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449 December 4, 2008				Attorney Docket No. 056291-5215		Application No. 10/554,202	
				Applicants: Robert Hugh BRADBURY et al.			
				Filing Date: October 24, 2005		Group Art Unit: 1624	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
/T.N./	21.	Klutchko et al. "Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors" J Med Chem. 49(4):1475-1485 (2006) .					
/T.N./	22.	Petrov et al. "Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series" Bioorg Med Chem Lett. 16(17):4686-4691 (2006) .					
Examiner		/Tamthom Truong/		Date Considered		05/07/2009	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							